1
|
Chen Q, Cao J, Kong H, Chen R, Wang Y, Zhou P, Huang W, Cheng H, Li L, Gao S, Feng J. SERS biosensors based on catalytic hairpin self-assembly and hybridization chain reaction cascade signal amplification strategies for ultrasensitive microRNA-21 detection. Mikrochim Acta 2024; 191:468. [PMID: 39023836 DOI: 10.1007/s00604-024-06552-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2024] [Accepted: 07/06/2024] [Indexed: 07/20/2024]
Abstract
A highly sensitive surface-enhanced Raman scattering (SERS) biosensor has been developed for the detection of microRNA-21 (miR-21) using an isothermal enzyme-free cascade amplification method involving catalytic hairpin assembly (CHA) and hybridization chain reaction (HCR). The CHA reaction is triggered by the target miR-21, which causes hairpin DNA (C1 and C2) to self-assemble into CHA products. After AgNPs@Capture captures the resulting CHA product, the HCR reaction is started, forming long-stranded DNA on the surface of AgNPs. A strong SERS signal is generated due to the presence of a large amount of the Raman reporter methylene blue (MB) in the vicinity of the SERS "hot spot" on the surface of AgNPs. The monitoring of the SERS signal changes of MB allows for the highly sensitive and specific detection of miR-21. In optimal conditions, the biosensor exhibits a satisfactory linear range and a low detection limit for miR-21 of 42.3 fM. Additionally, this SERS biosensor shows outstanding selectivity and reproducibility. The application of this methodology to clinical blood samples allows for the differentiation of cancer patients from healthy controls. As a result, the CHA-HCR amplification strategy used in this SERS biosensor could be a useful tool for miRNA detection and early cancer screening.
Collapse
Affiliation(s)
- Qiying Chen
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/College of Biological and Chemical Engineering, Guangxi University of Science and Technology, No. 257 Liushi Road, Yufeng District, Liuzhou City, 545006, Guangxi Zhuang Autonomous Region, PR China
| | - Jinru Cao
- Dongguan Key Laboratory of Precision Molecular Diagnostics, Prenatal Diagnosis Center, Dongguan Songshan Lake Central Hospital, Dongguan, 523200, Guangdong, PR China
| | - Hongxing Kong
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/College of Biological and Chemical Engineering, Guangxi University of Science and Technology, No. 257 Liushi Road, Yufeng District, Liuzhou City, 545006, Guangxi Zhuang Autonomous Region, PR China
- Provine and Ministry Co-Sponsored Collaborative Innovation Center of Sugarcane and Sugar Industry, Nanning, 530004, Guangxi, PR China
| | - Ruijue Chen
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/College of Biological and Chemical Engineering, Guangxi University of Science and Technology, No. 257 Liushi Road, Yufeng District, Liuzhou City, 545006, Guangxi Zhuang Autonomous Region, PR China
- Provine and Ministry Co-Sponsored Collaborative Innovation Center of Sugarcane and Sugar Industry, Nanning, 530004, Guangxi, PR China
| | - Ying Wang
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/College of Biological and Chemical Engineering, Guangxi University of Science and Technology, No. 257 Liushi Road, Yufeng District, Liuzhou City, 545006, Guangxi Zhuang Autonomous Region, PR China
- Provine and Ministry Co-Sponsored Collaborative Innovation Center of Sugarcane and Sugar Industry, Nanning, 530004, Guangxi, PR China
| | - Pei Zhou
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/College of Biological and Chemical Engineering, Guangxi University of Science and Technology, No. 257 Liushi Road, Yufeng District, Liuzhou City, 545006, Guangxi Zhuang Autonomous Region, PR China
- Provine and Ministry Co-Sponsored Collaborative Innovation Center of Sugarcane and Sugar Industry, Nanning, 530004, Guangxi, PR China
| | - Wenyi Huang
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/College of Biological and Chemical Engineering, Guangxi University of Science and Technology, No. 257 Liushi Road, Yufeng District, Liuzhou City, 545006, Guangxi Zhuang Autonomous Region, PR China
- Provine and Ministry Co-Sponsored Collaborative Innovation Center of Sugarcane and Sugar Industry, Nanning, 530004, Guangxi, PR China
| | - Hao Cheng
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/College of Biological and Chemical Engineering, Guangxi University of Science and Technology, No. 257 Liushi Road, Yufeng District, Liuzhou City, 545006, Guangxi Zhuang Autonomous Region, PR China
- Provine and Ministry Co-Sponsored Collaborative Innovation Center of Sugarcane and Sugar Industry, Nanning, 530004, Guangxi, PR China
| | - Lijun Li
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/College of Biological and Chemical Engineering, Guangxi University of Science and Technology, No. 257 Liushi Road, Yufeng District, Liuzhou City, 545006, Guangxi Zhuang Autonomous Region, PR China
- Provine and Ministry Co-Sponsored Collaborative Innovation Center of Sugarcane and Sugar Industry, Nanning, 530004, Guangxi, PR China
| | - Si Gao
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/College of Biological and Chemical Engineering, Guangxi University of Science and Technology, No. 257 Liushi Road, Yufeng District, Liuzhou City, 545006, Guangxi Zhuang Autonomous Region, PR China.
| | - Jun Feng
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/College of Biological and Chemical Engineering, Guangxi University of Science and Technology, No. 257 Liushi Road, Yufeng District, Liuzhou City, 545006, Guangxi Zhuang Autonomous Region, PR China.
| |
Collapse
|
2
|
Chen Q, Chen H, Kong H, Chen R, Gao S, Wang Y, Zhou P, Huang W, Cheng H, Li L, Feng J. Enzyme-free sensitive SERS biosensor for the detection of thalassemia-associated microRNA-210 using a cascade dual-signal amplification strategy. Anal Chim Acta 2024; 1292:342255. [PMID: 38309848 DOI: 10.1016/j.aca.2024.342255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Revised: 12/28/2023] [Accepted: 01/15/2024] [Indexed: 02/05/2024]
Abstract
BACKGROUND β-thalassemia is a blood disorder caused by autosomal mutations. Gene modulation therapy to activate the γ-globin gene to induce fetal hemoglobin (HbF) synthesis has become a new option for the treatment of β-thalassemia. MicroRNA-210 (miR-210) contributes to studying the mechanism regulating γ-globin gene expression and is a potential biomarker for rapid β-thalassemia screening. Traditional miRNA detection methods perform well but necessitate complex and time-consuming miRNA sample processing. Therefore, the development of a sensitive, accurate, and simple miRNA level monitoring method is essential. RESULTS We have developed a non-enzymatic surface-enhanced Raman scattering (SERS) biosensor utilizing a signal cascade amplification of catalytic hairpin assembly reaction (CHA) and proximity hybridization-induced hybridization chain reaction (HCR). Au@Ag NPs were used as the SERS substrate, and methylene blue (MB)- modified DNA hairpins were used as the SERS tags. The SERS assay involved two stages: implementing the CHA-HCR cascade signal amplification strategy and conducting SERS measurements on the resulting product. The HCR was started by the products of target-triggered CHA, which formed lengthy nicked double-stranded DNA (dsDNA) on the Au@Ag NPs surface to which numerous SERS tags were attached, leading to a significant increase in the SERS signal intensity. High specificity and sensitivity for miR-210 detection was achieved by monitoring MB SERS intensity changes. The suggested SERS biosensor has a low detection limit of 5.13 fM and is capable of detecting miR-210 at concentration between 10 fM and 1.0 nM. SIGNIFICANCE The biosensor can detect miR-210 levels in the erythrocytes of β-thalassemia patients, enabling rapid screening for β-thalassemia and suggesting a novel approach for investigating the regulation mechanism of miR-210 on γ-globin gene expression. In the meantime, this innovative technique has the potential to detect additional miRNAs and to become an important tool for the early diagnosis of diseases and for biomedical research.
Collapse
Affiliation(s)
- Qiying Chen
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/ College of Biological and Chemical Engineering, Guangxi University of Science and Technology, Liuzhou, 545006, Guangxi, PR China
| | - Huagan Chen
- Department of Clinical Laboratory, Liuzhou Maternity and Child Healthcare Hospital, Liuzhou, 545001, Guangxi, PR China
| | - Hongxing Kong
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/ College of Biological and Chemical Engineering, Guangxi University of Science and Technology, Liuzhou, 545006, Guangxi, PR China; Provine and Ministry Co-sponsored Collaborative Innovation Center of Sugarcane and Sugar Industry, Nanning, 530004, Guangxi, PR China
| | - Ruijue Chen
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/ College of Biological and Chemical Engineering, Guangxi University of Science and Technology, Liuzhou, 545006, Guangxi, PR China
| | - Si Gao
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/ College of Biological and Chemical Engineering, Guangxi University of Science and Technology, Liuzhou, 545006, Guangxi, PR China
| | - Ying Wang
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/ College of Biological and Chemical Engineering, Guangxi University of Science and Technology, Liuzhou, 545006, Guangxi, PR China
| | - Pei Zhou
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/ College of Biological and Chemical Engineering, Guangxi University of Science and Technology, Liuzhou, 545006, Guangxi, PR China
| | - Wenyi Huang
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/ College of Biological and Chemical Engineering, Guangxi University of Science and Technology, Liuzhou, 545006, Guangxi, PR China; Provine and Ministry Co-sponsored Collaborative Innovation Center of Sugarcane and Sugar Industry, Nanning, 530004, Guangxi, PR China
| | - Hao Cheng
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/ College of Biological and Chemical Engineering, Guangxi University of Science and Technology, Liuzhou, 545006, Guangxi, PR China; Provine and Ministry Co-sponsored Collaborative Innovation Center of Sugarcane and Sugar Industry, Nanning, 530004, Guangxi, PR China
| | - Lijun Li
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/ College of Biological and Chemical Engineering, Guangxi University of Science and Technology, Liuzhou, 545006, Guangxi, PR China; Provine and Ministry Co-sponsored Collaborative Innovation Center of Sugarcane and Sugar Industry, Nanning, 530004, Guangxi, PR China.
| | - Jun Feng
- Guangxi Key Laboratory of Green Processing of Sugar Resources, Department of Medicine/ College of Biological and Chemical Engineering, Guangxi University of Science and Technology, Liuzhou, 545006, Guangxi, PR China.
| |
Collapse
|
3
|
Zhou X, Qiang Z, Zhang S, Zhou Y, Xiao Q, Tan G. Evaluating the relationship between Clinical G6PD enzyme activity and gene variants. PeerJ 2024; 12:e16554. [PMID: 38188142 PMCID: PMC10771088 DOI: 10.7717/peerj.16554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Accepted: 11/09/2023] [Indexed: 01/09/2024] Open
Abstract
Glucose-6-phosphate dehydrogenase (G6PD) is a the first and rate-limiting enzyme that plays a critical role in G6PD deficiency, the most common enzyme disorder worldwide, is related to intravascular hemolysis. To determine the clinical enzyme activity level in different G6PD variants, we evaluated 15 variant from 424 clinical blood samples by using multicolor melting curve analysis and DNA sequencing. The results showed that the enzyme activities of the hemizygous deficient were 1.5-2.4 U/gHb, which was significantly lower than those of the heterozygous (P < 0.001) and the compound heterozygous variants (P < 0.05). Since the hemizygous of c.1024C > T (Chinese-5) mutation affects the kinetic parameters of G6PD and increase utilization of analogues, its enzyme activity is more than those of other mutations that mutated in the β+α region of G6PD. The heterozygous enzyme levels ranged from 6.5-20.1 U/gHb; and there was no significant difference among different heterozygous variants (P > 0.05). The enzyme activity levels of the compound heterozygous mutation were mainly in the range of 1.7-3.8 U/gHb, which was much lower than that of the heterozygous mutation (P < 0.001). In summary, our findings revealed that the enzyme activity of G6PD in blood have a significant relationship with genotype of G6PD.
Collapse
Affiliation(s)
- Xinyi Zhou
- Department of Clinical Laboratory & Zhuhai Institute of Medical Genetics, Zhuhai Maternity and Child Healthcare Hospital, Zhuhai, Guangdong, China
| | - Zheng Qiang
- Pathology Department, Zhuhai Maternity and Child Healthcare Hospital, Zhuhai, China
| | - Sufen Zhang
- Department of Clinical Laboratory & Zhuhai Institute of Medical Genetics, Zhuhai Maternity and Child Healthcare Hospital, Zhuhai, Guangdong, China
| | - Yuqiu Zhou
- Department of Clinical Laboratory & Zhuhai Institute of Medical Genetics, Zhuhai Maternity and Child Healthcare Hospital, Guangdong, China
| | - Qizhi Xiao
- Department of Clinical Laboratory & Zhuhai Institute of Medical Genetics, Zhuhai Maternity and Child Healthcare Hospital, Zhuhai, Guangdong, China
| | - Gongjun Tan
- Department of Clinical Laboratory & Zhuhai Institute of Medical Genetics, Zhuhai Maternity and Child Healthcare Hospital, Zhuhai, Guangdong, China
| |
Collapse
|
4
|
Clinical Performance Study of a New Fully Automated Red Blood Cell Permeability Fragility Analyzer. JOURNAL OF HEALTHCARE ENGINEERING 2022; 2022:5642907. [PMID: 35392140 PMCID: PMC8983219 DOI: 10.1155/2022/5642907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 03/11/2022] [Accepted: 03/12/2022] [Indexed: 11/21/2022]
Abstract
In order to verify the applicability of the erythrocyte fragility test (EFT) carried out by the new fully automatic erythrocyte permeability fragility analyzer RA-800 for thalassemia screening, a total of 100 cases of suspected thalassemia patients who underwent pregnancy examinations at Luohu District People's Hospital are included. The results of a new automatic erythrocyte permeability fragility analyzer RA-800 are compared with the results of the detection system composing of the KOFA erythrocyte fragility test kit currently used in clinical laboratories. The diagnosis confirmed by genetic testing is used as the gold standard to evaluate the applicability of RA-800. The sensitivity, specificity, and accuracy of the new automatic erythrocyte permeability fragility analyzer RA-800 screening for thalassemia were 66.67%, 92.86%, and 85.00%. The KOFA direct colorimetries are 76.67%, 81.43%, and 80.00%. The kappa value for the screening of thalassemia was 0.558, which concludes that the consistency was moderate. The ROC curve indicates that both two methods had diagnostic significance for the diagnostic value of thalassemia. The new automatic erythrocyte permeability fragility analyzer RA-800 is suitable for thalassemia screening, and the performance indexes meet the clinical requirements.
Collapse
|
5
|
Wu H, Huang Q, Yu Z, Zhong Z. Molecular analysis of alpha- and beta-thalassemia in Meizhou region and comparison of gene mutation spectrum with different regions of southern China. J Clin Lab Anal 2021; 35:e24105. [PMID: 34752669 PMCID: PMC8649333 DOI: 10.1002/jcla.24105] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2021] [Revised: 10/07/2021] [Accepted: 10/28/2021] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Thalassemia is a group of inherited autosomal recessive hemolytic anemia disease caused by reduced or absent synthesis of globin chain/chains of hemoglobin. Only few studies showed the molecular characterization of α- and β-thalassemia in Meizhou city of China. METHODS A total of 22,401 individuals were collected; hematological and hemoglobin electrophoresis analysis and thalassemia genetic testing were performed. RESULTS Eleven thousand and thirty (49.24%) cases with microcytosis (mean corpuscular volume (MCV) < 82 fl), 11,074 (49.44%) cases with hypochromia (mean corpuscular Hb (MCH) < 27 pg) in 22,401 subjects, 11,085 cases with abnormal hemoglobin results were identified in subjects aged ≥6 months. 7,322 (32.69%) subjects harbored thalassemia mutations, including 4,841 (21.61%) subjects with α-thalassemia, 2,237 (9.99%) with β-thalassemia, and 244 (1.09%) with α-thalassemia combined β-thalassemia. 18 genotypes of α-thalassemia mutations and 27 genotypes of β-thalassemia mutations were characterized. The most frequent α gene mutation was --SEA (64.69%), followed by -α3.7 (19.93%), -α4.2 (7.73%), αCS α (3.97%), and αWS α (2.83%). The six most common β-thalassemia mutations were IVS-II-654 (C>T) (39.79%), CD41-42 (-TCTT) (33.02%), -28 (A>G) (10.38%), CD17 (A>T) (9.08%), CD27-28 (+C) (2.14%), and CD26 (G>A) (2.02%). In addition, MCV and MCH were sensitive markers for α- and β-thalassemia except for -α3.7 /αα, -α4.2 /αα, αCS α/αα, αWS α/αα, and βCap+40-43 /βN . CONCLUSIONS The --SEA , -α3.7 , and -α4.2 deletions were the main mutations of α-thalassemia, while IVS-II-654 (C>T), CD41-42 (-TCTT), -28 (A>G), and CD17 (A>T) mutations of β-thalassemia in Meizhou. There were some differences in thalassemia mutation frequencies in Meizhou city from other populations in China.
Collapse
Affiliation(s)
- Heming Wu
- Center for Precision MedicineMeizhou People's Hospital (Huangtang Hospital)Meizhou Academy of Medical SciencesMeizhouChina
- Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translational Research of Hakka PopulationMeizhou People's Hospital (Huangtang Hospital)Meizhou Academy of Medical SciencesMeizhouChina
- Guangdong Provincial Engineering and Technology Research Center for Clinical Molecular Diagnostics and Antibody TherapeuticsMeizhou People's Hospital (Huangtang Hospital)Meizhou Academy of Medical SciencesMeizhouChina
| | - Qingyan Huang
- Center for Precision MedicineMeizhou People's Hospital (Huangtang Hospital)Meizhou Academy of Medical SciencesMeizhouChina
- Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translational Research of Hakka PopulationMeizhou People's Hospital (Huangtang Hospital)Meizhou Academy of Medical SciencesMeizhouChina
- Guangdong Provincial Engineering and Technology Research Center for Clinical Molecular Diagnostics and Antibody TherapeuticsMeizhou People's Hospital (Huangtang Hospital)Meizhou Academy of Medical SciencesMeizhouChina
| | - Zhikang Yu
- Center for Precision MedicineMeizhou People's Hospital (Huangtang Hospital)Meizhou Academy of Medical SciencesMeizhouChina
- Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translational Research of Hakka PopulationMeizhou People's Hospital (Huangtang Hospital)Meizhou Academy of Medical SciencesMeizhouChina
- Guangdong Provincial Engineering and Technology Research Center for Clinical Molecular Diagnostics and Antibody TherapeuticsMeizhou People's Hospital (Huangtang Hospital)Meizhou Academy of Medical SciencesMeizhouChina
| | - Zhixiong Zhong
- Center for Precision MedicineMeizhou People's Hospital (Huangtang Hospital)Meizhou Academy of Medical SciencesMeizhouChina
- Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translational Research of Hakka PopulationMeizhou People's Hospital (Huangtang Hospital)Meizhou Academy of Medical SciencesMeizhouChina
- Guangdong Provincial Engineering and Technology Research Center for Clinical Molecular Diagnostics and Antibody TherapeuticsMeizhou People's Hospital (Huangtang Hospital)Meizhou Academy of Medical SciencesMeizhouChina
| |
Collapse
|
6
|
He S, Li D, Yi S, Huang X, Zhou C, Chen B, Zuo Y, Lin L, Chen F, Wei H. Molecular Characterization of α- and β-Thalassaemia Among Children From 1 to 10 Years of Age in Guangxi, A Multi-Ethnic Region in Southern China. Front Pediatr 2021; 9:724196. [PMID: 34497785 PMCID: PMC8419341 DOI: 10.3389/fped.2021.724196] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2021] [Accepted: 07/27/2021] [Indexed: 11/13/2022] Open
Abstract
Background: Thalassemia is one of the most common genetic diseases in southern China. Howerver, population in different regions or different population has their own spectrums of thalassemia. To investigate the prevalence and spectrum features of thalassemia among children in Guangxi. Hematology and genetic analysis were performed on 71,459 children aged 1-10 years in various regions of Guangxi. Results: A total of 11,821 children were diagnoses with thalassemia including 7,615 (10.66%) subjects of α-thalassemia, 3,507 (4.90%) subjects of β-thalassemia, and 699 (0.98%) cases with both α- and β-thalassemia. Nine α-thalassemia mutations and 30 genotypes were identified among the α-thalassemia children. The - -SEA and - -SEA/αα were the most frequent mutation and genotype, respectively. One α-thalassemia fusion gene and a rare 2.4 kb deletion both causing α+-thalassemia were identified, respectively. Thirteen β-thalassemia mutations and 31 genotypes were characterized among the β-thalassemia children, with the most common mutation CD41-42 (-CTTT) accounting for 46.05% of the β-mutations. Two rare mutations IVS-II-5 (G>C), and IVS-I-2 (T>C) were firstly identified. Furthermore, 92 genotypes were identified among 699 children with both α- and β-thalassemia. Conclusions: Our findings highlight the great heterogeneity and the extensive spectrum of thalassemia among children in Guangxi, which provide an available reference for prevention of thalassemia in this area.
Collapse
Affiliation(s)
- Sheng He
- Key Laboratory of Basic Research for Guangxi Birth Defects Control and Prevention, Guangxi Zhuang Autonomous Region Women and Children Care Hospital, Nanning, China
| | - Dongming Li
- Key Laboratory of Basic Research for Guangxi Birth Defects Control and Prevention, Guangxi Zhuang Autonomous Region Women and Children Care Hospital, Nanning, China
| | - Shang Yi
- Key Laboratory of Basic Research for Guangxi Birth Defects Control and Prevention, Guangxi Zhuang Autonomous Region Women and Children Care Hospital, Nanning, China
| | - Xiuning Huang
- Key Laboratory of Basic Research for Guangxi Birth Defects Control and Prevention, Guangxi Zhuang Autonomous Region Women and Children Care Hospital, Nanning, China
| | - Chaofan Zhou
- Key Laboratory of Basic Research for Guangxi Birth Defects Control and Prevention, Guangxi Zhuang Autonomous Region Women and Children Care Hospital, Nanning, China
| | - Biyan Chen
- Key Laboratory of Basic Research for Guangxi Birth Defects Control and Prevention, Guangxi Zhuang Autonomous Region Women and Children Care Hospital, Nanning, China
| | - Yangjin Zuo
- Key Laboratory of Basic Research for Guangxi Birth Defects Control and Prevention, Guangxi Zhuang Autonomous Region Women and Children Care Hospital, Nanning, China
| | - Li Lin
- Key Laboratory of Basic Research for Guangxi Birth Defects Control and Prevention, Guangxi Zhuang Autonomous Region Women and Children Care Hospital, Nanning, China
| | - Faqin Chen
- Department of Laboratory Medicine, Youjiang Medical University for Nationalities, Baise, China
| | - Hongwei Wei
- Key Laboratory of Basic Research for Guangxi Birth Defects Control and Prevention, Guangxi Zhuang Autonomous Region Women and Children Care Hospital, Nanning, China
| |
Collapse
|
7
|
Huang TL, Zhang TY, Song CY, Lin YB, Sang BH, Lei QL, Lv Y, Yang CH, Li N, Tian X, Yang YH, Zhang XW. Gene Mutation Spectrum of Thalassemia Among Children in Yunnan Province. Front Pediatr 2020; 8:159. [PMID: 32351918 PMCID: PMC7174584 DOI: 10.3389/fped.2020.00159] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2020] [Accepted: 03/20/2020] [Indexed: 01/24/2023] Open
Abstract
Background: Thalassemia is an autosomal genetic disorder, found throughout the world. It is still not treatable and create socio economic problems. In this study, we investigated the prevalence and spectrum features of thalassemia in Yunnan Province, the southwestern area of China. During 2014-2018, a total of 3,539 suspected thalassemia children were detected with α- and β-thalassemia mutations by gap-Polymerase Chain Reaction (PCR) and reverse dot blot (RDB) analysis in Kunming Children's Hospital. Results: Of these patients, 1,130 were diagnosed thalassemia gene carriers with a carrying rate of 31.92%. Among them, α-thalassemia was 43.63%, β-thalassemia was 53.98%, cases with both α- and β- thalassemia was 2.39%. In α-thalassemia patients, the most common mutations was -SEA/αα (52.13%), followed by -α3.7/αα (27.79%), hemoglobin H disease (18.46%), and -α4.2/αα (1.62%). Fifteen gene mutations and 30 genotypes were identified in β-thalassemia patients, with the five most common mutations CD17 (A>T) (29.51%), CD41-42 (-TTCT) (27.87%), IVS-II-654 (C>T) (14.92%), CD26 (G>A) (6.89%), and CD26/CD27 (2.62%) accounting for 81.81% of the β-globin gene mutations. Furthermore, we founded two rare mutations CD34 (TGG → TAG) and Int in Chinese populations. Conclusions: Our results suggested that the prevalence and gene mutation spectrum of thalassemia display obviously heterogeneity among children in Yunnan Province. The findings provide the valuable information for premarital and pre-pregnancy screening, prenatal diagnostic services, and designing appropriate prevention programs to control thalassemia for future in this area.
Collapse
Affiliation(s)
- Ti-Long Huang
- Department of Hematology, Kunming Children's Hospital, Kunming, China
| | - Tian-Yao Zhang
- Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Chun-Yan Song
- Department of Hematology, Kunming Children's Hospital, Kunming, China
| | - Yun-Bi Lin
- Department of Hematology, Kunming Children's Hospital, Kunming, China
| | - Bao-Hua Sang
- Department of Hematology, Kunming Children's Hospital, Kunming, China
| | - Qing-Ling Lei
- Department of Hematology, Kunming Children's Hospital, Kunming, China
| | - Yu Lv
- Department of Hematology, Kunming Children's Hospital, Kunming, China
| | - Chun-Hui Yang
- Department of Hematology, Kunming Children's Hospital, Kunming, China
| | - Na Li
- Department of Hematology, Kunming Children's Hospital, Kunming, China
| | - Xin Tian
- Department of Hematology, Kunming Children's Hospital, Kunming, China
| | - Yue-Huang Yang
- Department of Hematology, Kunming Children's Hospital, Kunming, China
| | - Xian-Wen Zhang
- Medical Faculty, Kunming University of Science and Technology, Kunming, China
| |
Collapse
|
8
|
Wu H, Zhu Q, Zhong H, Yu Z, Zhang Q, Huang Q. Analysis of genotype distribution of thalassemia and G6PD deficiency among Hakka population in Meizhou city of Guangdong Province. J Clin Lab Anal 2019; 34:e23140. [PMID: 31793705 PMCID: PMC7171329 DOI: 10.1002/jcla.23140] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Revised: 10/14/2019] [Accepted: 11/15/2019] [Indexed: 11/13/2022] Open
Abstract
Objective The aim of the study was to explore genotype distribution thalassemia and G6PD deficiency in Meizhou city, China. Methods A total of 16 158 individuals were involved in thalassemia genetic testing. A total of 605 subjects were screened for common Chinese G6PD mutations by gene chip analysis. Genotypes and allele frequencies were analyzed. Results A total of 5463 cases carried thalassemia mutations were identified, including 3585 cases, 1701 cases, and 177 cases with α‐, β‐, and α + β‐thalassemia mutations, respectively. ‐‐SEA (65.12%), ‐α3.7 (19.05%), and ‐α4.2 (8.05%) deletion were the main mutations of α‐thalassemia, while IVS‐II‐654(C → T) (40.39%), CD41‐42(‐TCTT) (32.72%), ‐28(A → G) (10.11%), and CD17(A → T) (9.32%) mutations were the principal mutations of β‐thalassemia in Meizhou. There were significant differences in allele frequencies in some counties. Genetic testing for G6PD deficiency, six mutation sites, and one polymorphism were detected in our study. A total of 198 alleles with the mutation were detected among 805 alleles (24.6%). G6PD Canton (c.1376 G → T) (45.96%), G6PD Kaiping (c.1388 G → A) (39.39%), and G6PD Gaohe (c.95 A → G) (9.09%) account for 94.44% mutations, followed by G6PD Chinese‐5 (c.1024 C → T) (4.04%), G6PD Viangchan (c.871G → A) (1.01%), and G6PD Maewo (c.1360 C → T) (0.51%). There were some differences of the distribution of G6PD mutations among eight counties in Meizhou. Conclusions The ‐‐SEA, ‐α3.7, and ‐α4.2 deletion were the main mutations of α‐thalassemia, while IVS‐II‐654(C → T), CD41‐42(‐TCTT), ‐28(A → G), and CD17(A → T) mutations were the principal mutations of β‐thalassemia in Meizhou. G6PD c.1376 G → T, c.1388 G → A, and c.95 A → G were the main mutations of G6PD deficiency. There were some differences of the distribution of thalassemia and G6PD mutations among eight counties in Meizhou.
Collapse
Affiliation(s)
- Heming Wu
- Center for Precision Medicine, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China.,Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translational Research of Hakka Population, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China.,Guangdong Provincial Engineering and Technology Research Center for Clinical Molecular Diagnostics and Antibody Therapeutics, Meizhou, China.,Meizhou Municipal Engineering and Technology Research Center for Molecular Diagnostics of Major Genetic Disorders, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China
| | - Qiuyan Zhu
- Center for Precision Medicine, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China.,Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translational Research of Hakka Population, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China.,Guangdong Provincial Engineering and Technology Research Center for Clinical Molecular Diagnostics and Antibody Therapeutics, Meizhou, China.,Meizhou Municipal Engineering and Technology Research Center for Molecular Diagnostics of Major Genetic Disorders, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China
| | - Hua Zhong
- Center for Precision Medicine, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China.,Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translational Research of Hakka Population, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China.,Guangdong Provincial Engineering and Technology Research Center for Clinical Molecular Diagnostics and Antibody Therapeutics, Meizhou, China.,Meizhou Municipal Engineering and Technology Research Center for Molecular Diagnostics of Major Genetic Disorders, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China
| | - Zhikang Yu
- Center for Precision Medicine, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China.,Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translational Research of Hakka Population, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China.,Guangdong Provincial Engineering and Technology Research Center for Clinical Molecular Diagnostics and Antibody Therapeutics, Meizhou, China.,Meizhou Municipal Engineering and Technology Research Center for Molecular Diagnostics of Major Genetic Disorders, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China
| | - Qunji Zhang
- Center for Precision Medicine, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China.,Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translational Research of Hakka Population, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China.,Guangdong Provincial Engineering and Technology Research Center for Clinical Molecular Diagnostics and Antibody Therapeutics, Meizhou, China.,Meizhou Municipal Engineering and Technology Research Center for Molecular Diagnostics of Major Genetic Disorders, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China
| | - Qingyan Huang
- Center for Precision Medicine, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China.,Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translational Research of Hakka Population, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China.,Guangdong Provincial Engineering and Technology Research Center for Clinical Molecular Diagnostics and Antibody Therapeutics, Meizhou, China.,Meizhou Municipal Engineering and Technology Research Center for Molecular Diagnostics of Major Genetic Disorders, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou Hospital Affiliated to Sun Yat-sen University, Meizhou, China
| |
Collapse
|